Inhibits MCF-7 breast cancer cells growth and induces DNA fragmentation by apoptosis, accompanied by a downregulation of Bcl-2 protein expression and PARP cleavage by Caspase-3. This treatment increases the level of p21 WAF1/CIP1 protein in a p53-dependent manner. This evidence concerns the gene BCL2 and breast carcinoma.